1. Home
  2. NVNI vs BDSX Comparison

NVNI vs BDSX Comparison

Compare NVNI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.25

Market Cap

12.9M

Sector

N/A

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$17.88

Market Cap

122.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
BDSX
Founded
2019
2005
Country
Brazil
United States
Employees
618
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NVNI
BDSX
Price
$1.25
$17.88
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
85.1K
153.6K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
$6.67
$23.35
Revenue Next Year
$26.67
$19.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$0.14
$0.25
52 Week High
$4.94
$20.21

Technical Indicators

Market Signals
Indicator
NVNI
BDSX
Relative Strength Index (RSI) 36.29 62.47
Support Level $1.10 $6.33
Resistance Level $1.64 N/A
Average True Range (ATR) 0.13 1.84
MACD 0.04 0.20
Stochastic Oscillator 39.54 65.98

Price Performance

Historical Comparison
NVNI
BDSX

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: